MAFD1
MCID: MJR007
MIFTS: 42

Major Affective Disorder 1 (MAFD1)

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Major Affective Disorder 1

MalaCards integrated aliases for Major Affective Disorder 1:

Name: Major Affective Disorder 1 57 29 13 70
Bipolar Affective Disorder 57 29 6 32
Bipolar Affective Disorder, Susceptibility to 6
Manic-Depressive Psychosis, Autosomal 57
Bipolar Affective Disorder; Bpad 57
Manic-Depressive Psychosis; Md1 57
Manic-Depressive Psychosis 57
Bipolar Disorder 70
Mafd1 57
Bpad 57
Md1 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant


HPO:

31
major affective disorder 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM® 57 125480
ICD10 32 F31 F31.9
MedGen 41 C1852197
UMLS 70 C0005586 C1852197

Summaries for Major Affective Disorder 1

MalaCards based summary : Major Affective Disorder 1, also known as bipolar affective disorder, is related to bipolar disorder and major affective disorder 2. An important gene associated with Major Affective Disorder 1 is MAFD1 (Major Affective Disorder 1). The drugs Eleuthero and Coal tar have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are depressivity and mania

More information from OMIM: 125480

Related Diseases for Major Affective Disorder 1

Diseases in the Major Affective Disorder 1 family:

Major Affective Disorder 2 Major Affective Disorder 3
Major Affective Disorder 4 Major Affective Disorder 5
Major Affective Disorder 6 Major Affective Disorder 8
Major Affective Disorder 7 Major Affective Disorder 9

Diseases related to Major Affective Disorder 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 210)
# Related Disease Score Top Affiliating Genes
1 bipolar disorder 31.2 TPH2 MAFD1
2 major affective disorder 2 11.6
3 major affective disorder 5 11.5
4 major affective disorder 6 11.5
5 mental retardation, x-linked, syndromic 13 11.5
6 major affective disorder 4 11.4
7 major affective disorder 3 11.4
8 major affective disorder 7 11.3
9 myotonic dystrophy 1 11.3
10 schizophrenia 10.8
11 depression 10.7
12 bipolar i disorder 10.6
13 major depressive disorder 10.6
14 personality disorder 10.5
15 obsessive-compulsive disorder 10.5
16 schizoaffective disorder 10.5
17 alcohol dependence 10.4
18 tardive dyskinesia 10.4
19 hypothyroidism 10.4
20 substance abuse 10.4
21 major affective disorder 8 10.4
22 major affective disorder 9 10.4
23 mental depression 10.4
24 borderline personality disorder 10.4
25 huntington disease 10.3
26 attention deficit-hyperactivity disorder 10.3
27 parkinsonism 10.3
28 cyclothymic disorder 10.3
29 neurotic disorder 10.3
30 anxiety 10.3
31 hydrocephalus 10.3
32 dementia 10.3
33 thalassemia 10.3
34 yemenite deaf-blind hypopigmentation syndrome 10.2
35 depersonalization disorder 10.2
36 psychotic disorder 10.2
37 melancholia 10.2
38 mood disorder 10.2
39 schizophrenia 1 10.2
40 frontotemporal dementia 10.2
41 mental health wellness 1 10.2
42 mental health wellness 2 10.2
43 alacrima, achalasia, and mental retardation syndrome 10.2
44 exanthem 10.2
45 physical disorder 10.2
46 thalassemia minor 10.2
47 movement disease 10.2
48 panic disorder 10.2
49 severe combined immunodeficiency 10.2
50 adenoma 10.2

Graphical network of the top 20 diseases related to Major Affective Disorder 1:



Diseases related to Major Affective Disorder 1

Symptoms & Phenotypes for Major Affective Disorder 1

Human phenotypes related to Major Affective Disorder 1:

31
# Description HPO Frequency HPO Source Accession
1 depressivity 31 HP:0000716
2 mania 31 HP:0100754

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Neurologic Behavioral Psychiatric Manifestations:
depression with mania (bipolar 1)
depression with hypomania (bipolar 2)

Clinical features from OMIM®:

125480 (Updated 05-Apr-2021)

Drugs & Therapeutics for Major Affective Disorder 1

Drugs for Major Affective Disorder 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 423)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Eleuthero Approved, Experimental Phase 4
2
Coal tar Approved Phase 4 8007-45-2
3
Donepezil Approved Phase 4 120014-06-4 3152
4
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
5
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
6
Clozapine Approved Phase 4 5786-21-0 2818
7
Loxapine Approved Phase 4 1977-10-2 3964
8
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
9
Sertraline Approved Phase 4 79617-96-2 68617
10
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
11
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
12
Norepinephrine Approved Phase 4 51-41-2 439260
13
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
14
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
15
Topiramate Approved Phase 4 97240-79-4 5284627
16
Galantamine Approved Phase 4 357-70-0 9651
17
Memantine Approved, Investigational Phase 4 19982-08-2 4054
18
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
19
Inositol Approved, Investigational, Withdrawn Phase 4 87-89-8
20
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
21
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
22
Oxcarbazepine Approved Phase 4 28721-07-5 34312
23
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
24
Nortriptyline Approved Phase 4 72-69-5 4543
25
Iloperidone Approved Phase 4 133454-47-4 71360
26
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
27
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
28
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
29
Ondansetron Approved Phase 4 99614-02-5 4595
30
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
31
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
32
Levetiracetam Approved Phase 4 102767-28-2 441341
33
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
34
Dipyridamole Approved Phase 4 58-32-2 3108
35
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
36
Atorvastatin Approved Phase 4 134523-00-5 60823
37
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
38
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
39
Metformin Approved Phase 4 657-24-9 4091 14219
40
Nicotine Approved Phase 4 54-11-5 942 89594
41
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
42
Racepinephrine Approved Phase 4 329-65-7 838
43
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
44
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
45
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
46
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
47
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
48
Simvastatin Approved Phase 4 79902-63-9 54454
49
Losartan Approved Phase 4 114798-26-4 3961
50
Lorazepam Approved Phase 4 846-49-1 3958

Interventional clinical trials:

(show top 50) (show all 1275)
# Name Status NCT ID Phase Drugs
1 Assessing the Efficacy of Left Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunctive Treatment to Mood Stabilizers for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
2 Algorithm Guided Treatment Strategies for Bipolar Depression Unknown status NCT01938859 Phase 4 Lithium;Quetiapine;Shuganjieyu capsule
3 Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder Unknown status NCT02478788 Phase 4 mixed amphetamine salts-extended release (MAS-XR);Placebo
4 Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
5 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
6 An Open Label, Multicenter, Single Arm, 4-Week Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
7 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
8 A Randomized Controlled Trial to Evaluate the Effectiveness of Clozapine Versus Olanzapine, Quetiapine or Risperidone in Treatment Resistant Bipolar Disorder Unknown status NCT02562287 Phase 4 Clozapine;Risperidone;Olanzapine;Quetiapine
9 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
10 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
11 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
12 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
13 A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression Unknown status NCT02719392 Phase 4 Minocycline
14 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
15 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
16 An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression Unknown status NCT03567681 Phase 4 Extended release oxcarbazepine vs Immediate release oxcarbazepine
17 Clinical Psychopharmacology Division Institute of Mental Health, Peking University Unknown status NCT03148535 Phase 4 Lithium Carbonate;lithium carbonate combined with SSRI antidepressant treatment
18 A Randomized Open-label Active-controlled Study to Evaluate the Efficacy and Safety of Utapine Versus Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
19 Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics Completed NCT01811160 Phase 4 Melatonin;Placebo
20 A Double-Blind, Placebo-Controlled Evaluation of The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania Completed NCT01191918 Phase 4 Donepezil and Lithium;Placebo plus Lithium
21 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
22 Open-Label Study of Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Spectrum Disorder Completed NCT00181922 Phase 4 ziprasidone (Geodon)
23 Open-Label Study of Divalproex Sodium Extended Release for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181727 Phase 4 divalproex sodium extended release
24 Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness. Completed NCT00067938 Phase 4 lamotrigine
25 An Open-labeled, Parallel-group, Single-blinded (Rater) Pilot Study to Investigate the Neuroprotective Effects of of Low-dose Lithium in Young Subjects at Ultra High Risk (UHR) of Developing a First-episode Psychotic Disorder Completed NCT00202306 Phase 4 lithium carbonate
26 A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of Self-administered ADASUVE® (Staccato Loxapine for Inhalation) in Agitated Patients Outside the Hospital Setting Completed NCT02525991 Phase 4
27 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
28 Open-Label Study of Concerta in the Treatment of ADHD in Youth and Adults With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181987 Phase 4 methylphenidate HCl (Concerta)
29 Open-Label Comparative Study of Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Spectrum Disorder Completed NCT00181935 Phase 4 risperidone (Risperdal);olanzapine (Zyprexa)
30 Open-Label Study of Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar and Bipolar Spectrum Disorder Completed NCT00181883 Phase 4 quetiapine
31 Open-Label Study of Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181870 Phase 4 carbamazepine ER (Equetro)
32 A Pilot Open Study of the Safety and Effectiveness of Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorders Completed NCT00181844 Phase 4 lamotrigine
33 Open-Label Pilot Study of Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181779 Phase 4 aripiprazole (Abilify)
34 Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking Completed NCT00621777 Phase 4 Varenicline;Placebo
35 Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium in Bipolar Disorder: Identification of Cellular and Molecular Targets Clinically Relevant Completed NCT01919892 Phase 4 Lithium
36 A Randomized, Open-label, Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide Completed NCT01416220 Phase 4 Lithium;Paroxetine
37 Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients Completed NCT02644577 Phase 4 Metformin
38 Acute Antidepressant Therapy in Bipolar II Major Depression Completed NCT00641927 Phase 4 Venlafaxine;Lithium Carbonate
39 A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression Completed NCT00186758 Phase 4
40 Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment With Abilify and Depakote Completed NCT00545675 Phase 4 Abilify(aripiprazole);Depakote (divalproate)
41 Multi-center, Single Arm, Open Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify With Depakote in the 6-week Treatment of Acute Mania in Patients With Bipolar Disorder Completed NCT00545142 Phase 4 Abilify(Aripiprazole);Depakote(Divalproate)
42 An Open-Label Extension Study to Assess the Safety of Lamotrigine in Subjects With Bipolar Disorder, Who Are in Remission Following a Manic/Hypomanic Index Episode or a Depressive Index Episode. Completed NCT00360126 Phase 4 lamotrigine
43 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder Completed NCT00167479 Phase 4 risperidone (Risperdal)
44 Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging Completed NCT02473250 Phase 4 Fluoxetine;Citalopram
45 A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder Completed NCT00484471 Phase 4 aripiprazole;valproate;placebo
46 Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial Completed NCT00305370 Phase 4 Aripiprazole
47 A Randomized, Double-blind, Placebo-controlled, Trial of Lamotrigine add-on Therapy in Outpatients With Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence Completed NCT00280293 Phase 4 Lamotrigine;Placebo
48 Lamictal As Add on Treatment in Mixed States of Bipolar Disorder Completed NCT00223509 Phase 4 Lamotrigine
49 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Alcohol Abuse/ Dependence. Completed NCT00223249 Phase 4 Quetiapine
50 Aripiprazole in Late Life Bipolar Disorder Completed NCT00194038 Phase 4 Aripiprazole

Search NIH Clinical Center for Major Affective Disorder 1

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carbamazepine
Clonazepam
Clozapine
CLOZAPINE (CARACO)
CLOZAPINE (CLOZARIL)
CLOZAPINE (IVAX)
CLOZAPINE (TEVA)
CLOZAPINE (VERSACLOZ)
Divalproex Sodium
Fazaclo
gabapentin
gabapentin enacarbil
lamotrigine
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Mylan brand of clozapine
olanzapine
quetiapine
Quetiapine fumarate
Risperidone
Sodium Valproate
tiagabine
Tiagabine hydrochloride
topiramate
UDL brand of clozapine
Valproic Acid

Genetic Tests for Major Affective Disorder 1

Genetic tests related to Major Affective Disorder 1:

# Genetic test Affiliating Genes
1 Major Affective Disorder 1 29
2 Bipolar Affective Disorder 29

Anatomical Context for Major Affective Disorder 1

MalaCards organs/tissues related to Major Affective Disorder 1:

40
Brain, Cortex, Prefrontal Cortex, Thyroid, Eye, Endothelial, Cingulate Cortex

Publications for Major Affective Disorder 1

Articles related to Major Affective Disorder 1:

(show top 50) (show all 2174)
# Title Authors PMID Year
1
Brain-specific tryptophan hydroxylase 2 (TPH2): a functional Pro206Ser substitution and variation in the 5'-region are associated with bipolar affective disorder. 61 6 57
17905754 2008
2
The first genomewide interaction and locus-heterogeneity linkage scan in bipolar affective disorder: strong evidence of epistatic effects between loci on chromosomes 2q and 6q. 61 57
17924339 2007
3
Genome-wide scan for genes involved in bipolar affective disorder in 70 European families ascertained through a bipolar type I early-onset proband: supportive evidence for linkage at 3p14. 57 61
16534504 2006
4
The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders: a meta-analysis. 61 57
15860340 2005
5
Linkage disequilibrium mapping of bipolar affective disorder at 12q23-q24 provides evidence for association at CUX2 and FLJ32356. 61 57
15389760 2005
6
Loci on chromosomes 6q and 6p interact to increase susceptibility to bipolar affective disorder in the national institute of mental health genetics initiative pedigrees. 57 61
15219468 2004
7
Novel CAG/CTG repeat expansion mutations do not contribute to the genetic risk for most cases of bipolar disorder or schizophrenia. 57 61
14681907 2004
8
A common mechanism of action for three mood-stabilizing drugs. 61 57
12015604 2002
9
A genome screen for genes predisposing to bipolar affective disorder detects a new susceptibility locus on 8q. 61 57
11741836 2001
10
Linkage of bipolar disorder to chromosome 18q and the validity of bipolar II disorder. 61 57
11695948 2001
11
Further evidence for a bipolar risk gene on chromosome 12q24 suggested by investigation of haplotype sharing and allelic association in patients from the Faroe Islands. 61 57
11443532 2001
12
An apparently dominant bipolar affective disorder (BPAD) locus on chromosome 20p11.2-q11.2 in a large Turkish pedigree. 61 57
11175298 2001
13
Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogeneous population in quebec points to a locus of major effect on chromosome 12q23-q24. 61 57
10490718 1999
14
Mitochondrial genetic analyses suggest selection against maternal lineages in bipolar affective disorder. 61 57
10417293 1999
15
A comprehensive linkage analysis of chromosome 21q22 supports prior evidence for a putative bipolar affective disorder locus. 57 61
9915960 1999
16
A genome-wide search for chromosomal loci linked to mental health wellness in relatives at high risk for bipolar affective disorder among the Old Order Amish. 57 61
9861003 1998
17
No evidence for significant linkage between bipolar affective disorder and chromosome 18 pericentromeric markers in a large series of multiplex extended pedigrees. 61 57
9529343 1998
18
Significant linkage between bipolar affective disorder and chromosome 12q24. 61 57
9800214 1998
19
Lack of linkage between the corticotropin-releasing hormone (CRH) gene and bipolar affective disorder. 57 61
9399692 1997
20
Two-locus admixture linkage analysis of bipolar and unipolar affective disorder supports the presence of susceptibility loci on chromosomes 11p15 and 21q22. 57 61
9119364 1997
21
A locus for bipolar affective disorder on chromosome 4p. 61 57
8630499 1996
22
A genome-wide search for chromosomal loci linked to bipolar affective disorder in the Old Order Amish. 57 61
8630500 1996
23
Evidence for linkage of bipolar disorder to chromosome 18 with a parent-of-origin effect. 61 57
8533768 1995
24
Linkage analyses of chromosome 18 markers do not identify a major susceptibility locus for bipolar affective disorder in the Old Order Amish. 61 57
7668292 1995
25
Patterns of maternal transmission in bipolar affective disorder. 57 61
7762550 1995
26
Genetics of bipolar affective disorder: time for another reinvention? 61 57
7762549 1995
27
A possible vulnerability locus for bipolar affective disorder on chromosome 21q22.3. 61 57
7874172 1994
28
Exclusion of close linkage of bipolar disorder to the Gs-alpha subunit gene in nine Australian pedigrees. 57 61
7531727 1994
29
Anticipation in bipolar affective disorder. 61 57
8328456 1993
30
A genome-wide search for genes predisposing to manic-depression, assuming autosomal dominant inheritance. 61 57
8503452 1993
31
Genetic linkage analysis of bipolar affective disorder in an Old Order Amish pedigree. 61 57
1551659 1992
32
Bipolar affective disorder and thalassemia minor. 61 57
3717440 1986
33
Variant GADL1 and response to lithium in bipolar I disorder. 57
24806173 2014
34
Variant GADL1 and response to lithium in bipolar I disorder. 57
24806172 2014
35
Variant GADL1 and response to lithium in bipolar I disorder. 57
24806174 2014
36
Variant GADL1 and response to lithium in bipolar I disorder. 57
24806175 2014
37
Variant GADL1 and response to lithium in bipolar I disorder. 57
24806177 2014
38
Variant GADL1 and response to lithium in bipolar I disorder. 57
24806176 2014
39
Variant GADL1 and response to lithium therapy in bipolar I disorder. 57
24369049 2014
40
Genetics of bipolar disorder. 57
23663951 2013
41
A cytogenetic abnormality and rare coding variants identify ABCA13 as a candidate gene in schizophrenia, bipolar disorder, and depression. 57
19944402 2009
42
Functional properties of missense variants of human tryptophan hydroxylase 2. 6
19319927 2009
43
Genetics of bipolar disorder: successful start to a long journey. 57
19144440 2009
44
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. 57
18711365 2008
45
BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. 57
18562287 2008
46
Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. 57
18319075 2008
47
Molecular genetics of bipolar disorder and depression. 57
17239033 2007
48
Familial pathways to suicidal behavior--understanding and preventing suicide among adolescents. 57
17192535 2006
49
Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. 57
16402137 2006
50
Illness-specific association of val66met BDNF polymorphism with performance on Wisconsin Card Sorting Test in bipolar mood disorder. 57
16222333 2006

Variations for Major Affective Disorder 1

ClinVar genetic disease variations for Major Affective Disorder 1:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TPH2 NM_173353.4(TPH2):c.616C>T (p.Pro206Ser) SNV risk factor 3164 rs17110563 GRCh37: 12:72366306-72366306
GRCh38: 12:71972526-71972526
2 CLCN2 NM_004366.6(CLCN2):c.740G>T (p.Gly247Val) SNV Uncertain significance 523471 rs1553856477 GRCh37: 3:184075440-184075440
GRCh38: 3:184357652-184357652

Expression for Major Affective Disorder 1

Search GEO for disease gene expression data for Major Affective Disorder 1.

Pathways for Major Affective Disorder 1

GO Terms for Major Affective Disorder 1

Sources for Major Affective Disorder 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....